<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Adakveo-4874 EN PI</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\, Car17\, Car17 Car\,- H19\,Annotationtext\,Car17\,Car6\,Char\,Char Char Char\,Char Char1\,Comment Text Char Char\,Comment Text Char Char Char\,Comment Text Char Char1\,Comment Text Char1\,Comment Text Char1 Char\,Comment Text Char2 Char\,Kommentartext";
	mso-style-link:"Comment Text Char\, Car17 Char\, Car17 Car Char\,- H19 Char\,Annotationtext Char\,Car17 Char\,Car6 Char\,Char Char\,Char Char Char Char\,Char Char1 Char\,Comment Text Char Char Char1\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\, Car17 Char\, Car17 Car Char\,- H19 Char\,Annotationtext Char\,Car17 Char\,Car6 Char\,Char Char\,Char Char Char Char\,Char Char1 Char\,Comment Text Char Char Char1\,Comment Text Char Char Char Char\,Comment Text Char Char1 Char";
	mso-style-link:"Comment Text\, Car17\, Car17 Car\,- H19\,Annotationtext\,Car17\,Car6\,Char\,Char Char Char\,Char Char1\,Comment Text Char Char\,Comment Text Char Char Char\,Comment Text Char Char1\,Comment Text Char1\,Comment Text Char1 Char\,Comment Text Char2 Char\,Kommentartext";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Calibri",sans-serif;}
p.Text, li.Text, div.Text
	{mso-style-name:"Text\,Graphic\,Graphic Char Char\,Graphic Char Char Char Char Char\,Graphic Char Char Char Char Char Char Char C\,Italic\,JP Body Text\,Text_10394\,graphics\,non tochic\,notic\,\672C\6587";
	mso-style-link:"Text Char\,Graphic Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.TextChar
	{mso-style-name:"Text Char\,Graphic Char";
	mso-style-link:"Text\,Graphic\,Graphic Char Char\,Graphic Char Char Char Char Char\,Graphic Char Char Char Char Char Char Char C\,Italic\,JP Body Text\,Text_10394\,graphics\,non tochic\,notic\,\672C\6587";
	font-family:"MS Mincho";}
p.Table, li.Table, div.Table
	{mso-style-name:"Table\,10 pt\,10 pt  Bold\,9 pt";
	mso-style-link:"Table Char\,10 pt  Bold Char\,10 pt Char\,9 pt Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.TableChar
	{mso-style-name:"Table Char\,10 pt  Bold Char\,10 pt Char\,9 pt Char";
	mso-style-link:"Table\,10 pt\,10 pt  Bold\,9 pt";
	font-family:"Arial",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Comment, li.Comment, div.Comment
	{mso-style-name:Comment;
	mso-style-link:"Comment Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:#BF30B5;
	font-style:italic;}
span.CommentChar
	{mso-style-name:"Comment Char";
	mso-style-link:Comment;
	font-family:"MS Mincho";
	color:#BF30B5;
	font-style:italic;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
p.Dedicatednumber, li.Dedicatednumber, div.Dedicatednumber
	{mso-style-name:Dedicatednumber;
	margin-top:.5in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
p.Listlevel1, li.Listlevel1, div.Listlevel1
	{mso-style-name:"List level 1";
	mso-style-link:"List level 1 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.Listlevel1Char
	{mso-style-name:"List level 1 Char";
	mso-style-link:"List level 1";
	font-family:"MS Mincho";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
p.Standard, li.Standard, div.Standard
	{mso-style-name:Standard;
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.Kommentarzeichen
	{mso-style-name:Kommentarzeichen;}
span.CommentTextChar2
	{mso-style-name:"Comment Text Char2\,- H19 Char1\,Annotationtext Char1\,Comment Text Char Char Char Char1\,Comment Text Char Char Char2\,Comment Text Char Char1 Char1\,Comment Text Char1 Char Char1\,Comment Text Char1 Char2\,Comment Text Char2 Char Char1\,Kommentartext Char";
	font-family:"Times New Roman",serif;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><img width=21 height=18
src="Adakveo-4874%20EN%20PI_files/image001.png"><span lang=EN-GB>This medicinal
product is subject to additional monitoring. This will allow quick
identification of new safety information. Healthcare professionals are asked to
report any suspected adverse reactions. See section&nbsp;4.8 for how to report
adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.       NAME OF </span></b><b><span
lang=EN-GB>THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo
10&nbsp;mg/ml concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.       QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each ml of
concentrate for solution for infusion contains 10&nbsp;mg crizanlizumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of
10&nbsp;ml contains 100&nbsp;mg crizanlizumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Crizanlizumab is
a monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by
recombinant DNA technology.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.       PHARMACEUTICAL </span></b><b><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif'>FORM</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><a name="_Toc259706902"></a><a
name="_Toc259707071"></a><a name="_Toc259707134"></a><a name="_Toc259713075"><span
lang=EN-GB>Concentrate for solution for infusion</span></a><span lang=EN-GB>
(sterile concentrate)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Colourless to
slightly brownish&#8209;yellow liquid at pH&nbsp;6 and with an osmolality of
300&nbsp;mOsm/kg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.       </span></b><b><span
lang=EN-GB>CLINICAL</span></b><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1     Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Standard><span lang=EN-GB>Adakveo</span><span lang=EN-GB> is indicated
for the prevention of recurrent vaso&#8209;occlusive crises (VOCs) in sickle
cell disease patients aged 16&nbsp;years and older. It can be given as an add&#8209;on
therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients
for whom HU/HC is inappropriate or inadequate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.2     Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated by physicians experienced in the management of </span><span
lang=EN-GB>sickle cell disease.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u><a name="_nth_Adults_and_patients_ag4131"></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose of crizanlizumab is 5&nbsp;mg/kg administered over a period of
30&nbsp;minutes by intravenous infusion at week&nbsp;0, week&nbsp;2, and every
4&nbsp;weeks thereafter.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Crizanlizumab </span><span
lang=EN-GB>c</span><span lang=EN-GB>an be given alone or with HU/HC.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Standard style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If a dose is missed, the treatment should be administered as soon as
possible.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt'><span
style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>If crizanlizumab is administered
within 2&nbsp;weeks after the missed dose, dosing should be continued according
to the patient’s original schedule.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt'><span
style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>If crizanlizumab is administered
more than 2&nbsp;weeks after the missed dose, dosing should be continued every
4&nbsp;weeks thereafter.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Special populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Crizanlizumab
has not been studied in elderly patients. No dose adjustment is required as the
pharmacokinetics of crizanlizumab in adults are not affected by age.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Based on the
population pharmacokinetic (PK) results, no dose adjustment is required in
patients with mild or moderate renal impairment (see section&nbsp;5.2). Data
from patients with severe renal impairment are too limited to draw conclusions
on this population.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of crizanlizumab in patients with hepatic impairment have not been
established. Crizanlizumab is a monoclonal antibody and is cleared via
catabolism (i.e. breakdown into peptides and amino acids), and a change in dose
is not expected to be required for patients with hepatic impairment (see
section</span><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span><span
lang=EN-GB>5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=Standard style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of </span><span lang=EN-GB>crizanlizumab</span><span lang=EN-GB> in
paediatric patients from 6&nbsp;months to 16&nbsp;years have not been
established. No data are available.</span></p>

<p class=Standard style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Standard style='line-height:normal'><span lang=EN-GB>There is no
relevant use of crizanlizumab in infants aged less than 6&nbsp;months for the
indication of prevention of recurrent vaso&#8209;occlusive crises.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo </span><span
lang=EN-GB>should be diluted with sodium chloride 9&nbsp;mg/ml (0.9%) solution
for injection or dextrose 5% before administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The diluted solution</span><span
lang=EN-GB> must be administered through a sterile, non&#8209;pyrogenic 0.2&nbsp;micron
in&#8209;line filter by intravenous infusion over a period of 30&nbsp;minutes. It
must not be administered by intravenous push or bolus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For instructions
on dilution of the medicinal product before administration, see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to Chinese Hamster Ovary (CHO) cell products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4     Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In order to
improve the traceability of biological medicinal products, the name and the
batch number of the administered product should be clearly recorded.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Infusion&#8209;related reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In clinical
studies, infusion&#8209;related reactions (defined as occurring within
24&nbsp;hours) were observed in 2&nbsp;patients (1.8%) treated with crizanlizumab
5&nbsp;mg/kg</span><span lang=EN-GB>. Patients should be monitored for signs
and symptoms of infusion&#8209;related reactions, which may include fever,
chills, nausea, vomiting, fatigue, dizziness, pruritus, urticaria, sweating,
shortness of breath or wheezing. </span><span lang=EN-GB>In the event of a
severe reaction, crizanlizumab should be discontinued and appropriate therapy
should be instituted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Laboratory test interference: automated platelet counts</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interference
with automated platelet counts (platelet clumping) has been observed in
patients treated with crizanlizumab in clinical studies, in particular when
tubes containing EDTA (ethylenediaminetetraacetic acid) were used. This may
lead to unevaluable or falsely decreased platelet counts. There is no evidence
that crizanlizumab causes a reduction in circulating platelets or has a pro&#8209;aggregant
effect <i>in vivo</i>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To mitigate the
potential for laboratory test interference, it is recommended to run the test as
soon as possible (within 4&nbsp;hours of blood collection) or use citrate
tubes. When needed, </span><span lang=EN-GB>platelet counts can be estimated via
a peripheral blood smear</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Excipients with known effect</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, that is to say
essentially “sodium&#8209;free”.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5     Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interactions
between crizanlizumab and other medicinal products have not been investigated
in dedicated studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monoclonal
antibodies are not metabolised by cytochrome P450 (CYP450) enzymes. Therefore,
medicinal products that are substrates, inhibitors or inducers of CYP450 are
not expected to affect the pharmacokinetics of crizanlizumab. In clinical
studies, HU/HC had no effect on crizanlizumab pharmacokinetics in patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No effect on
exposure of co&#8209;administered medicinal products is expected based on the
metabolic pathways of monoclonal antibodies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6     </span></b><b><span
lang=EN-GB>Fertility, p</span></b><b><span lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Standard><span lang=EN-GB>There is a limited amount of data from the
use of Adakveo in pregnant women. Based on data from animal studies, crizanlizumab
has the potential to cause foetal losses when administered to a pregnant woman
(see section&nbsp;5.3). As a precautionary measure, it is preferable to avoid
the use of Adakveo during pregnancy and in woman of childbearing potential not
using contraception.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Standard style='line-height:normal'>To help determine the effects in
pregnant women, healthcare professionals are encouraged to report all pregnancy
cases and complications during pregnancy (from 105&nbsp;days prior to the last
menstrual period onward) to <span lang=EN-GB>the local representative of the</span>
marketing authorisation holder (see package leaflet), in order to allow
monitoring of these patients through the PRegnancy outcomes Intensive
Monitoring programme (PRIM). In addition, all adverse pregnancy events should
be reported <span lang=EN-GB>via <span style='color:black;background:#D9D9D9'>the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:#D9D9D9'>Appendix V</span></a></span>.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown whether
crizanlizumab is excreted in human milk after administration of Adakveo. There
are no data on the effects of crizanlizumab on the breast&#8209;fed newborn/infant
or on milk production.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Because many
medicinal products, including antibodies, can be excreted in human milk, a risk
to the newborn/infant cannot be excluded.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A decision must
be made whether to discontinue breast&#8209;feeding or to discontinue Adakveo
therapy, taking into account the benefit of breast&#8209;feeding for the child
and the benefit of therapy for the woman.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data on the effect of Adakveo on human fertility. Available non&#8209;clinical
data do not suggest an effect on fertility under crizanlizumab treatment (see
section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7     Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo may have
a minor influence on the ability to drive and use machines. Dizziness, fatigue
and somnolence may occur following administration of crizanlizumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Summary of the safety profile</span></u><a
name="_nth_Summary_of_the_safety_6118"></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The most frequently reported adverse drug reactions (&#8805;10% of
patients) in the Adakveo 5&nbsp;mg/kg group were arthralgia, nausea, back pain,
pyrexia and abdominal pain. Severe events were observed for pyrexia and
arthralgia (each 0.9%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Table&nbsp;1 lists adverse reactions based on pooled data from two
studies: the pivotal study, SUSTAIN, and a single&#8209;arm, open&#8209;label
pharmacokinetics/pharmacodynamics and safety study. Use of crizanlizumab in
combination with HU/HC did not result in any meaningful differences in the
safety profile.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Within each system organ class, the adverse reactions are ranked by
frequency, with the most frequent reactions first. Within each frequency
grouping, adverse reactions are presented in order of decreasing seriousness.
In addition, the corresponding frequency category for each adverse reaction is
based on the following convention: very common (&#8805;1/10); common
(&#8805;1/100 to &lt;1/10); uncommon (&#8805;1/1,000 to &lt;1/100); rare
(&#8805;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><a name="_Toc272145403"></a><a name="_Toc272145564"></a><a
name="_Toc266768477"></a><a name="_Toc260903679"></a><a name="_Toc266264818"></a><a
name="_Toc499550967"></a><a name="_Toc517716325"><b><span lang=EN-GB>Table&nbsp;1       Adverse
reactions in clinical studies</span></b></a><a
name="_hd6_Table_7_1_Percentage_o7395"></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='width:459.0pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=234 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text style='margin-top:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>System organ class</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text style='margin-top:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Frequency</span></b></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text style='margin-top:0in;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Adverse reaction</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=234 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Respiratory, thoracic and
  mediastinal disorders</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Oropharyngeal pain</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=234 rowspan=2 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Very common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Nausea, abdominal pain*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.45pt'>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>D</span><span lang=EN-GB
  style='font-size:11.0pt'>iarrhoea, vomiting</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=234 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Skin and subcutaneous tissue
  disorders</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Pruritus*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=234 rowspan=2 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Musculoskeletal and
  connective tissue disorders</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Very common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Arthralgia, back pain</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Myalgia, musculoskeletal
  chest pain</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=234 rowspan=2 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>General disorders and
  administration site conditions</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Very common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Pyrexia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Infusion site reaction*</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=234 valign=top style='width:175.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Injury, poisoning and
  procedural complications</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Common</span></p>
  </td>
  <td width=270 valign=top style='width:202.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>Infusion&#8209;related
  reaction</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=612 colspan=3 valign=top style='width:459.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>*The
  following groupings contain the following MedDRA preferred terms:</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Abdominal
  pain: abdominal pain, abdominal pain upper, abdominal pain lower, abdominal
  discomfort, and abdominal tenderness</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><span lang=FR-CH style='font-family:
  "Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pruritus:
  pruritus and vulvovaginal pruritus</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=FR-CH style='font-family:"Times New Roman",serif'>Infusion
  site reaction: infusion site extravasation, infusion site pain, and infusion
  site swelling</span></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><i><u><span style='font-size:11.0pt'>Immunogenicity</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>In clinical studies, treatment&#8209;induced anti&#8209;crizanlizumab
antibodies were transiently detected in 1&nbsp;patient (0.9%) among the 111&nbsp;patients
who received Adakveo 5&nbsp;mg/kg.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>There was no evidence of altered pharmacokinetics or of
an altered safety profile with anti&#8209;crizanlizumab antibody development.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Standard style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=Standard style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>Frequency, type and severity of adverse reactions in
patients aged 16 and 17&nbsp;years are expected to be the same as in adults.
The safety of crizanlizumab was evaluated in 3&nbsp;patients aged &lt;18&nbsp;years.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='color:black;
background:#D9D9D9'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:#D9D9D9'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>No cases of overdose have been reported in clinical studies.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>General supportive
measures and symptomatic treatment should be initiated in cases of suspected
overdose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacotherapeutic group: Other haematological agents, ATC code: B06AX01</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Crizanlizumab is a selective IgG2 kappa humanised monoclonal
antibody (mAb) that binds to P&#8209;selectin with high affinity and blocks the
interaction with its ligands, including P&#8209;selectin glycoprotein ligand&nbsp;1.
</span><span lang=EN-GB>Crizanlizumab can also dissociate preformed P&#8209;selectin/PSGL&#8209;1
complex. </span><span lang=EN-GB>P&#8209;selectin is an adhesion molecule
expressed on activated endothelial cells and platelets. It plays an essential
role in the initial recruitment of leukocytes and the aggregation of platelets
to the site of vascular injury during inflammation. In the chronic pro&#8209;inflammatory
state associated with sickle cell disease, P&#8209;selectin is over&#8209;expressed
and circulating blood cells and the endothelium are activated and become
hyperadhesive. P&#8209;selectin&#8209;mediated multi&#8209;cellular adhesion is
a key factor in the pathogenesis of vaso&#8209;occlusion and vaso&#8209;occlusive
crises (VOC). Elevated levels of P&#8209;selectin are found in patients with
sickle cell disease.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Binding P&#8209;selectin on the surface of the activated endothelium
and platelets has been shown to effectively block interactions between
endothelial cells, platelets, red blood cells and leukocytes, thereby
preventing vaso&#8209;occlusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Throughout
clinical studies, treatment with crizanlizumab 5&nbsp;mg/kg resulted in dose&#8209;dependent,
immediate and sustained P&#8209;selectin inhibition </span><span lang=EN-GB>(as
measured <i>ex vivo</i>) </span><span lang=EN-GB>in patients with sickle cell disease.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The efficacy of crizanlizumab, with or without HU/HC, was evaluated
in the pivotal study SUSTAIN, a 52&#8209;week, randomised, placebo&#8209;controlled,
double&#8209;blind, multicentre clinical study in sickle cell disease patients
with a history of vaso&#8209;occlusive crises (VOCs).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In this study, VOCs were defined as those leading to a healthcare
visit, which captured all acute episodes of pain with no other cause than a
vaso&#8209;occlusive event that required a healthcare visit and treatment with
oral or parenteral opioids or parenteral non&#8209;steroidal anti&#8209;inflammatory
drugs (NSAIDs). Acute chest syndrome, hepatic sequestration, splenic
sequestration and priapism (requiring a healthcare visit), by definition, were
also considered VOCs.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A total of 198&nbsp;sickle cell disease patients aged 16 to 63&nbsp;years
(inclusive; mean age 30.1±10.3&nbsp;years), with any sickle cell disease genotype
(including HbSS [71.2%], HbSC [16.2%], HbSbeta0&#8209;thalassaemia [6.1%],
HbSbeta+&#8209;thalassaemia [5.1%], and others [1.5%]) and a history of between
2 and 10&nbsp;VOCs in the previous 12&nbsp;months (62.6% and 37.4% of the
patients had 2&#8209;4 or 5&#8209;10&nbsp;VOCs, respectively), were randomised
1:1:1 to Adakveo 5&nbsp;mg/kg, Adakveo 2.5&nbsp;mg/kg or placebo. The majority
of patients were Black or African American (91.9%). Patients received Adakveo with
(62.1%) or without (37.9%) HU/HC. Randomisation was stratified by patients
already receiving HU/HC (Y/N) and by number of VOCs in the previous 12&nbsp;months
(2 to 4, 5&nbsp;to 10). Patients were allowed to take medicinal products to
relieve pain (i.e. paracetamol, NSAIDs and opioids) and to receive occasional
transfusions on an “as needed” basis. Patients participating in a chronic
transfusion programme (pre-planned series of transfusions for prophylactic
purposes) were excluded from the study.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Treatment with Adakveo 5&nbsp;mg/kg resulted in a 45.3% lower median
annual rate of VOCs compared to placebo (Hodges&#8209;Lehmann, median absolute
difference of &#8209;1.01 compared with placebo, 95% CI [&#8209;2.00, 0.00]),
which was statistically significant (p=0.010). The median annual rates of uncomplicated
VOCs (any VOCs as defined above, excluding acute chest syndrome, hepatic
sequestration, splenic sequestration or priapism) and days hospitalised were
62.9% and 41.8% lower in the Adakveo 5&nbsp;mg/kg than in the placebo group,
respectively. The VOCs occurring during the study were assessed by an
independent review committee.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Main efficacy outcomes of the pivotal SUSTAIN study are summarised
in Tables&nbsp;2 and 3.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><a name="_Toc499550968"></a><a name="_Toc517716326"><b><span lang=EN-GB>Table&nbsp;</span></b></a><b><span
lang=EN-GB>2       Results from SUSTAIN clinical study in </span></b><a
name="_hd6_Table_12_1_Results_fro16811"></a><b><span lang=EN-GB>sickle cell
disease</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.84%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width="20%" valign=top style='width:20.16%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Event</span></b></p>
  </td>
  <td width="23%" valign=top style='width:23.82%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Adakveo 5&nbsp;mg/kg</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>(N=67)</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(standard median)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.54%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Placebo</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>(N=65)</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(standard median)</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Change vs placebo</span></b></p>
  </td>
  <td width="21%" valign=top style='width:21.1%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Hodges&#8209;Lehmann median
  difference</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(95% CI)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.9%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>p-value</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(Wilcoxon rank sum)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width="20%" valign=top style='width:20.18%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Primary endpoint</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Annual rate of VOCs</span></p>
  </td>
  <td width="23%" valign=top style='width:23.82%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>1.63</span></p>
  </td>
  <td width="11%" valign=top style='width:11.54%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>2.98</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;45.3%</span></p>
  </td>
  <td width="21%" valign=top style='width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;1.01</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;2.00, 0.00)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>0.010</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="87%" colspan=5 valign=top style='width:87.1%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Secondary endpoints</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width="20%" valign=top style='width:20.18%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Annual rate of days hospitalised</span></p>
  </td>
  <td width="23%" valign=top style='width:23.82%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>4.00</span></p>
  </td>
  <td width="11%" valign=top style='width:11.54%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>6.87</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;41.8%</span></p>
  </td>
  <td width="21%" valign=top style='width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>0.00</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;4.36, 0.00)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>0.450</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width="20%" valign=top style='width:20.18%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Annual rate of uncomplicated VOCs</span></p>
  </td>
  <td width="23%" valign=top style='width:23.82%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>1.08</span></p>
  </td>
  <td width="11%" valign=top style='width:11.54%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>2.91</span></p>
  </td>
  <td width="10%" valign=top style='width:10.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;62.9%</span></p>
  </td>
  <td width="21%" valign=top style='width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;1.00</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;1.98, 0.00)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>-</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:1.0pt'>
  <td width="0%" colspan=6 valign=top style='width:.02%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>The primary (annual rate of VOC leading
  to healthcare visit) and key secondary (annual rate of days hospitalised)
  endpoints were the only ones formally tested for statistical significance
  according to protocol.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The clinical effect demonstrated in the
primary efficacy analysis was supported by multiple supplementary analyses
including a negative binomial regression on investigator assessments with a
conservative method to handle missing data due to early discontinuation of
treatment based on outcomes in the placebo group (RR=0.74, 95% CI=0.52, 1.06).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the Adakveo 5&nbsp;mg/kg group, clinically significant reductions
in the annual rate of VOCs were observed across important subgroups (</span><span
lang=EN-GB>HU/HC use, 2&#8209;4 or 5&#8209;10&nbsp;VOCs in the previous 12&nbsp;months,
and HbSS or non&#8209;HbSS genotypes; </span><span lang=EN-GB>see Table&nbsp;3).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Table&nbsp;3       Annual rate of VOCs in patients &#8209;
subgroup analyses</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=121 valign=top style='width:90.45pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Subgroup </span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Adakveo 5&nbsp;mg/kg (N=67)</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(standard median)</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Placebo (N=65)</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(standard median)</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Change vs placebo</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Hodges&#8209;Lehmann median
  difference</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=121 rowspan=2 style='width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>HU/HC use</span></p>
  </td>
  <td width=85 style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Yes</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=42</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>2.43</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n= 40</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>3.58</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;32.1%</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;1.01</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;2.44, 0.00)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=85 style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>No</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=25</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>1.00</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=25</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>2.00</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;50.0%</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;1.02</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;2.00, 0.00)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.2pt'>
  <td width=121 rowspan=2 style='width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:20.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Number of VOCs in previous
  12&nbsp;months</span></p>
  </td>
  <td width=85 style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:20.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>2&#8209;4&nbsp;VOCs</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:20.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=42</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>1.14</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:20.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=41</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>2.00</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:20.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;43.0%</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:20.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;0.05</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;1.56, 0.01)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=85 style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>5&#8209;10&nbsp;VOCs</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=25</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>1.97</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=24</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>5.32</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;63.0%</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;2.74</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;5.00, &#8209;0.83)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=121 rowspan=2 style='width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Sickle cell disease genotypes,
  including HbSC</span></p>
  </td>
  <td width=85 style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>HbSS</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=47</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>1.97</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=47</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>3.01</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;34.6%</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;1.01</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;2.18, 0.00)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=85 style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Non&#8209;HbSS</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=20</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>0.99</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>n=18</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>2.00</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;50.5%</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&#8209;1.01</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>(&#8209;2.01, 0.00)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A greater than two&#8209;fold increase in the proportion of patients
with no VOC and who completed the study was observed in the Adakveo 5&nbsp;mg/kg
group compared to placebo (22% vs 8%; odds ratio [95% CI]: 3.57 [1.20, 10.63]).
A similar difference was also observed across important subgroups (HU/HC use,
genotype).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Treatment with Adakveo 5&nbsp;mg/kg was also associated with a three&#8209;fold
longer Kaplan&#8209;Meier estimated median time to first VOC compared with
placebo (4.07 vs 1.38&nbsp;months; HR=0.495, 95% CI: 0.331, 0.741) (Figure&nbsp;1)
and a two&#8209;fold longer median time from randomisation to second VOC
compared to placebo (10.32 vs 5.09&nbsp;months; HR=0.534, 95% CI: 0.329, 0.866).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Figure&nbsp;1      Kaplan&#8209;Meier curve of time to first VOC</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-top:0in;page-break-after:avoid'><span
style='position:absolute;z-index:251748352;left:0px;margin-left:61px;
margin-top:211px;width:13px;height:9px'><img width=13 height=9
src="Adakveo-4874%20EN%20PI_files/image002.png" alt=0></span><span
style='position:absolute;z-index:251746304;left:0px;margin-left:63px;
margin-top:190px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image003.png" alt=10></span><span
style='position:absolute;z-index:251744256;left:0px;margin-left:64px;
margin-top:169px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image004.png" alt=20></span><span
style='position:absolute;z-index:251742208;left:0px;margin-left:64px;
margin-top:149px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image005.png" alt=30></span><span
style='position:absolute;z-index:251740160;left:0px;margin-left:65px;
margin-top:130px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image006.png" alt=40></span><span
style='position:absolute;z-index:251738112;left:0px;margin-left:64px;
margin-top:110px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image007.png" alt=50></span><span
style='position:absolute;z-index:251736064;left:0px;margin-left:64px;
margin-top:90px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image008.png" alt=60></span><span
style='position:absolute;z-index:251734016;left:0px;margin-left:64px;
margin-top:70px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image009.png" alt=70></span><span
style='position:absolute;z-index:251731968;left:0px;margin-left:63px;
margin-top:48px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image010.png" alt=80></span><span
style='position:absolute;z-index:251729920;left:0px;margin-left:65px;
margin-top:28px;width:10px;height:10px'><img width=10 height=10
src="Adakveo-4874%20EN%20PI_files/image011.png" alt=90></span><span
style='position:absolute;z-index:251727872;left:0px;margin-left:60px;
margin-top:9px;width:15px;height:10px'><img width=15 height=10
src="Adakveo-4874%20EN%20PI_files/image012.png" alt=100></span><span
style='position:absolute;z-index:251781120;left:0px;margin-left:459px;
margin-top:8px;width:125px;height:38px'><img width=125 height=38
src="Adakveo-4874%20EN%20PI_files/image013.png"></span><span style='position:
absolute;z-index:251779072;left:0px;margin-left:494px;margin-top:7px;
width:92px;height:26px'><img width=92 height=26
src="Adakveo-4874%20EN%20PI_files/image014.png"></span><span style='position:
absolute;z-index:251666432;left:0px;margin-left:22px;margin-top:28px;
width:32px;height:178px'><img width=32 height=178
src="Adakveo-4874%20EN%20PI_files/image015.png"
alt="Probability of being free from first VOC (%)"></span><span
style='position:absolute;z-index:251725824;left:0px;margin-left:320px;
margin-top:242px;width:56px;height:10px'><img width=56 height=10
src="Adakveo-4874%20EN%20PI_files/image016.png" alt="Time (months)¬¬¬¬"></span><sub><span
style='font-size:11.0pt'>                                <img border=0
width=518 height=223 id="Picture 1243"
src="Adakveo-4874%20EN%20PI_files/image017.jpg"></span></sub></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=3 height=1></td>
  <td width=36></td>
  <td width=33></td>
  <td width=2></td>
  <td width=2></td>
  <td width=5></td>
  <td width=10></td>
  <td width=3></td>
  <td width=23></td>
  <td width=10></td>
  <td width=27></td>
  <td width=10></td>
  <td width=26></td>
  <td width=3></td>
  <td width=7></td>
  <td width=28></td>
  <td width=10></td>
  <td width=28></td>
  <td width=10></td>
  <td width=25></td>
  <td width=10></td>
  <td width=26></td>
  <td width=13></td>
  <td width=26></td>
  <td width=10></td>
  <td width=26></td>
  <td width=10></td>
  <td width=30></td>
  <td width=10></td>
  <td width=26></td>
  <td width=10></td>
  <td width=26></td>
  <td width=10></td>
  <td width=27></td>
  <td width=10></td>
  <td width=18></td>
 </tr>
 <tr>
  <td height=10></td>
  <td colspan=5></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image018.png" alt=0></td>
  <td colspan=2></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image019.png" alt=1></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image020.png" alt=2></td>
  <td></td>
  <td colspan=2 align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image021.png" alt=3></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image022.png" alt=4></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image023.png" alt=5></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image024.png" alt=6></td>
  <td></td>
  <td align=left valign=top><img width=13 height=10
  src="Adakveo-4874%20EN%20PI_files/image025.png" alt=7></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image026.png" alt=8></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image027.png" alt=9></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image003.png" alt=10></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image028.png" alt=11></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image029.png" alt=12></td>
  <td></td>
  <td align=left valign=top><img width=10 height=10
  src="Adakveo-4874%20EN%20PI_files/image030.png" alt=13></td>
 </tr>
 <tr>
  <td height=14></td>
 </tr>
 <tr>
  <td height=9></td>
  <td colspan=7></td>
  <td colspan=6 align=left valign=top><img width=99 height=9
  src="Adakveo-4874%20EN%20PI_files/image031.png"
  alt="Number of patients at risk"></td>
 </tr>
 <tr>
  <td height=7></td>
 </tr>
 <tr>
  <td height=7></td>
  <td colspan=4></td>
  <td colspan=31 rowspan=5 align=left valign=top><img width=513 height=43
  src="Adakveo-4874%20EN%20PI_files/image032.png"
  alt="67,49,41,35,30,26,24,20,18,17,16,15,7,65,37,23,21,17,13,12,9,8,6,5,4,1,0,0"></td>
 </tr>
 <tr>
  <td height=10></td>
  <td colspan=3 align=left valign=top><img width=71 height=10
  src="Adakveo-4874%20EN%20PI_files/image033.png" alt="Adakveo 5 mg/kg "></td>
 </tr>
 <tr>
  <td height=14></td>
 </tr>
 <tr>
  <td height=10></td>
  <td></td>
  <td align=left valign=top><img width=33 height=10
  src="Adakveo-4874%20EN%20PI_files/image034.png" alt=Placebo></td>
 </tr>
 <tr>
  <td height=2></td>
 </tr>
</table>

<span lang=EN-GB>&nbsp;</span></p>

<p class=Text style='margin-top:0in;page-break-after:avoid'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text style='margin-top:0in;page-break-after:avoid'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name="_hd6_Table_2_1_Patients_wit18544"></a><u><span lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy of
crizanlizumab in patients aged 16 and 17&nbsp;years is expected to be the same
as in adults. Three patients (2.7%) aged less than 18&nbsp;years were treated
with crizanlizumab 5&nbsp;mg/kg in clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has deferred the obligation to submit the results of studies
with Adakveo in one or more subsets of the paediatric population in the
treatment of sickle cell disease (see section&nbsp;4.2 for information on
paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Conditional approval</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product has been authorised under a so&#8209;called “conditional approval”
scheme. This means that further evidence on this medicinal product is awaited.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency will review new information on this medicinal product at least
every year and this SmPC will be updated as necessary.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2     Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The median time
to reach maximum serum concentration of crizanlizumab (T<sub>max</sub>) was 1.92&nbsp;hours
at steady state following intravenous administration of 5&nbsp;mg/kg over a
period of 30&nbsp;minutes in sickle cell disease patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Crizanlizumab
distribution is typical of endogenous human antibodies within the vascular and
extracellular spaces. The volume of distribution (V<sub>z</sub>) was 4.26&nbsp;litres
after a single 5&nbsp;mg/kg intravenous infusion of crizanlizumab in healthy
volunteers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Antibodies are
primarily eliminated via proteolysis by lysosomal enzymes in the liver to small
peptides and amino acids.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In healthy
volunteers, the mean terminal elimination half&#8209;life (T<sub>½</sub>) was
10.6&nbsp;days and the mean clearance was 11.7&nbsp;ml/h at crizanlizumab dose
level 5&nbsp;mg/kg. In patients with sickle cell disease, the mean elimination T<sub>½</sub>
during the dosing interval was 7.5&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Linearity/non&#8209;linearity</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The exposure to
crizanlizumab (mean C<sub>max</sub>, AUC<sub>last</sub>, or AUC<sub>inf</sub>)
increased in non&#8209;linear manner over the dose range of 0.2 to 8&nbsp;mg/kg
in healthy volunteers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Renal impairment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a population
PK analysis in patients with eGFR ranging from 35 to 202&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>,
no clinically important differences in the pharmacokinetics of crizanlizumab
were found between patients with mild or moderate renal impairment and patients
with normal renal function. Data from patients with severe renal impairment are
too limited to draw conclusions on this population (see section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hepatic impairment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of crizanlizumab in patients with hepatic impairment have not been
established. Crizanlizumab is a monoclonal antibody and is cleared via
catabolism (i.e. breakdown into peptides and amino acids), and a change in dose
is not expected to be required for patients with hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric <a name="_nth_Pediatric_patients__be14752"></a>population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetics
in paediatric patients below the age of 16&nbsp;years have not been
investigated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3     Preclinical safety
data</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N</span><span
lang=EN-GB>on&#8209;clinical data revealed no special hazard for humans based
on conventional studies of safety pharmacology, tissue cross&#8209;reactivity
and repeated dose toxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the 26&#8209;week
repeated dose toxicity study, administration of crizanlizumab in cynomolgus
monkeys at dose levels up to 50&nbsp;mg/kg/dose once every 4&nbsp;weeks (at
least 13.5&nbsp;times the human clinical exposure based on AUC in patients with
sickle cell disease at 5&nbsp;mg/kg once every four weeks) was generally well tolerated.
There were no primary crizanlizumab&#8209;related findings on any endpoint
evaluated. At 50&nbsp;mg/kg, minimal to moderate inflammation of the vessels in
multiple tissues considered to be an antigen&#8209;antibody complex reaction
(primate antihuman antibody) was observed in 2 of 10&nbsp;animals. There was one
death attributed to aspiration of gastric contents following a peri&#8209;infusional
reaction mediated by anti&#8209;drug&#8209;antibody&#8209;dependent
hypersensitivity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Pharmacological effects of
crizanlizumab on haemodynamic and electrocardiographic parameters in the
cynomolgus monkey were evaluated in the 26&#8209;week repeated dose toxicology
study. Respiratory rate and neurological parameters were also assessed. There
were no crizanlizumab&#8209;related effects on arterial blood pressure or on
heart rate, PR, RR, QRS, QT, and heart rate corrected QT (QTc) intervals on the
electrocardiograms (ECG). No rhythm abnormalities or qualitative changes were
observed during the qualitative ECG assessment. There were no crizanlizumab&#8209;related
effects on respiration rate or any neurological parameter evaluated.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Formal
carcinogenicity, genotoxicity and juvenile toxicity studies have not been
conducted with crizanlizumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a 26&#8209;week
repeated dose toxicity study, cynomolgus monkeys were administered
crizanlizumab once every 4&nbsp;weeks at doses up to 50&nbsp;mg/kg (at least
13.5&nbsp;times the human clinical exposure based on AUC in patients with
sickle cell disease at 5&nbsp;mg/kg once every four weeks). </span><span
lang=EN-GB>There were no adverse effects of crizanlizumab on male and female
reproductive organs</span>.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In an enhanced
pre&#8209; and postnatal development study in cynomolgus monkeys, pregnant
animals received intravenous crizanlizumab once every two weeks during the
period of organogenesis, at doses of 10 and 50&nbsp;mg/kg (approximately 2.8
and 16&nbsp;times </span><span lang=EN-GB>the human clinical exposure based on
AUC in patients with sickle cell disease at 5&nbsp;mg/kg/dose once every four
weeks, respectively)</span><span lang=EN-GB>. No maternal toxicity was
observed. </span><span lang=EN-GB>There was an increase in foetal loss
(abortions or stillbirths) at both doses and this was higher in the third
trimester. The cause of the foetal losses in monkeys is unknown but may be due
to the development of anti&#8209;drug antibodies against crizanlizumab</span><span
lang=EN-GB>. There were no effects on infant growth and development during the 6&nbsp;months
postpartum that were attributable to crizanlizumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Measurable
crizanlizumab serum concentrations were observed in the infant monkeys at
postnatal day&nbsp;28, confirming that crizanlizumab, like other IgG
antibodies, crosses the placental barrier.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.       PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Sucrose</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Sodium citrate (E331)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Citric acid (E330)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Polysorbate 80 (E433)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for
injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product</span><span lang=EN-GB> must not be mixed with other medicinal products
except those mentioned in section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Unopened vial</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>18&nbsp;months</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Diluted solution</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Chemical and
physical in&#8209;use stability, from the start of preparation of the diluted
solution for infusion until end of infusion, has been demonstrated for up to 8&nbsp;hours
at room temperature (up to 25°C) and at 2°C to 8°C for up to 24&nbsp;hours
overall.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>From a microbiological point of view, the diluted
solution for infusion should be used immediately. If not used immediately, in&#8209;use
storage times and conditions prior to use are the responsibility of the user
and would normally not be longer than 24&nbsp;hours at 2°C to 8°C, including
4.5&nbsp;hours at room temperature (up to 25°C) from the start of preparation
to completion of the infusion, unless dilution has taken place in controlled
and validated aseptic conditions.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4     Special precautions
for storage</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator
(2°C&nbsp;–&nbsp;8°C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage conditions
after dilution of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5     Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10&nbsp;ml concentrate
for solution for infusion in a type&nbsp;I glass vial with a coated chlorobutyl
rubber stopper sealed with an aluminium cap with a plastic flip&#8209;off disk containing
100&nbsp;mg crizanlizumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack of 1&nbsp;vial.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6     Special
precautions for disposal and other handling</span></b></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo vials
are for single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Preparing the infusion</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The diluted
solution for infusion should be prepared by a healthcare professional using
aseptic techniques.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The total dose
and required volume of Adakveo depend on the patient’s body weight; 5&nbsp;mg
of crizanlizumab is administered per kg body weight.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The volume to be used for the preparation of the infusion is
calculated according to the following equation:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=567
 style='margin-left:12.5pt;border-collapse:collapse'>
 <tr>
  <td width=113 rowspan=2 style='width:85.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>Volume (ml) =</span></p>
  </td>
  <td width=359 style='width:269.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
  text-indent:-28.35pt;line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Patient’s body weight (kg) x prescribed dose</span></p>
  </td>
  <td width=94 style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
  text-indent:-28.35pt;line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>[5&nbsp;mg/kg]</span></p>
  </td>
 </tr>
 <tr>
  <td width=359 style='width:269.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>Concentration
  of Adakveo</span></p>
  </td>
  <td width=94 style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>[10&nbsp;mg/ml]</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><a
name="_hd6_Table_3_1_Example_of_d12477"></a><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1.       Obtain the number of
vials required to deliver the prescribed dose and bring them to room
temperature (for a maximum of 4&nbsp;hours). One vial is needed for every
10&nbsp;ml of Adakveo (see below table).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=568
 style='margin-left:28.35pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Body weight (kg)</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Dose (mg)</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Volume (ml)</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Vials (n)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>40</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>200</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>20</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>2</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>60</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>300</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>30</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>3</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>80</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>400</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>40</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>100</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>500</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>50</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>5</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>120</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>600</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>60</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>6</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>2.       Visually inspect the vials.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The solution in the vials should be clear to
opalescent. Do not use if particles are present in the solution.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The solution should be colourless or may have a
slight brownish&#8209;yellow tint.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>3.       Withdraw a volume
equal to the required volume of Adakveo from a 100&nbsp;ml infusion bag containing
either sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection or dextrose
5% and discard.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>No incompatibilities between the diluted Adakveo
solution and infusion bags composed of polyvinylchloride (PVC), polyethylene
(PE) and polypropylene (PP) have been observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4.       Withdraw the necessary
volume of Adakveo from the vials and inject slowly into the previously prepared
infusion bag.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The </span><span lang=EN-GB>solution</span><span
lang=EN-GB> must not be mixed or co&#8209;administered with other medicinal
products through the same intravenous line.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep the volume of Adakveo added to the infusion
bag in the range of 10&nbsp;ml&nbsp;to&nbsp;96&nbsp;ml to obtain a final
concentration in the infusion bag within 1&nbsp;mg/ml to 9.6&nbsp;mg/ml.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5.       Mix the
diluted solution by gently inverting the infusion bag. DO NOT SHAKE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Administration</span></u><a name="_nth_Administration25012"></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>Adakveo diluted solution must be administered through
a sterile, non&#8209;pyrogenic 0.2&nbsp;micron in&#8209;line filter by
intravenous infusion over a period of 30&nbsp;minutes.</span><span
style='font-size:11.0pt'> <span lang=EN-GB>No incompatibilities have been
observed between Adakveo and infusion sets composed of PVC, PE&#8209;lined PVC,
polyurethane, and in&#8209;line filter membranes composed of polyethersulfone
(PES), polyamide (PA) or polysulphone (PSU).</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
administration of Adakveo, flush the line with at least 25&nbsp;ml sodium
chloride 9&nbsp;mg/ml (0.9%) solution for injection or dextrose 5%.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Disposal</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.       MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.       MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>EU/1/20/1476/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines </span><span lang=EN-GB>Agency <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.<br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>A.      MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE
SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:77.9pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>D.      <span style='text-transform:uppercase'>conditions
or restrictions with regard to the safe and effective use of the medicinal
PRODUCT</span></span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>E.      SPECIFIC OBLIGATION TO COMPLETE
POST-AUTHORISATION MEASURES FOR THE </span></b><b><span lang=EN-GB>CONDITIONAL</span><span
lang=EN-GB> MARKETING AUTHORISATION</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>A.      MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE
SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Name and address of the manufacturer(s) of the biological active
substance(s)</span></u></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Standard style='line-height:normal'><span lang=DE-CH>Novartis Pharma
AG</span></p>

<p class=Standard style='line-height:normal'><span lang=DE-CH>Lichtstrasse 35</span></p>

<p class=Standard style='line-height:normal'><span lang=DE-CH>4056 Basel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Switzerland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Name and address of the manufacturer(s) responsible for batch
release</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Standard style='line-height:normal'>Novartis Pharma GmbH</p>

<p class=Standard style='line-height:normal'>Roonstrasse 25</p>

<p class=Standard style='line-height:normal'>90429 Nuremberg</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="OLE_LINK2"><b><span lang=EN-GB>B.</span></b></a><b><span
lang=EN-GB>      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>C.      OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The requirements for submission of PSURs for this medicinal product
are set out in the list of Union reference dates (EURD list) </span><span
lang=EN-GB>provided for under Article 107c(7) of Directive 2001/83</span><span
lang=EN-GB>/EC</span><span lang=EN-GB> and </span><span lang=EN-GB>any
subsequent updates published on the European medicines web&#8209;portal.</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The marketing
authorisation holder (MAH) shall submit the first PSUR for this product within
6&nbsp;months following authorisation.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>D.      CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The </span><span lang=EN-GB>marketing</span><span lang=EN-GB>
authorisation holder (</span><span lang=EN-GB>MAH) shall perform the required
pharmacovigilance activities and interventions detailed in the agreed RMP
presented in Module 1.8.2 of the marketing authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Standard style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Standard style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>E.      SPECIFIC OBLIGATION
TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING
AUTHORISATION</span></b></p>

<p class=Standard style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Standard style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>This being a conditional marketing authorisation and
pursuant to Article 14a(4) of Regulation (EC) No 726/2004, the MAH shall
complete, within the stated timeframe, the following measures:</span></p>

<p class=Standard style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=NormaleTabelle border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="82%" valign=top style='width:82.18%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Standard style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Description</span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Standard style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Due date</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="82%" valign=top style='width:82.18%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>In
  order to confirm the efficacy and safety of crizanlizumab, the MAH should
  submit the results of the primary analysis of a phase III CSEG101A2301 study
  of crizanlizumab with or without hydroxyurea/hydroxycarbamide in adolescent
  and adult sickle cell disease patients with vaso-occlusive crises</span></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Clinical
  study report primary analysis:</span></p>
  <p class=TabletextrowsAgency style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>December
  2025</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="82%" valign=top style='width:82.18%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>In
  order to confirm the efficacy and safety of crizanlizumab, the MAH should
  submit the final results of the phase&nbsp;II CSEG101A2202 study of
  crizanlizumab with or without hydroxyurea/hydroxycarbamide in sickle cell
  disease patients with vaso&#8209;occlusive crisis.</span></p>
  </td>
  <td width="17%" valign=top style='width:17.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Clinical
  study report:</span></p>
  <p class=TabletextrowsAgency style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>December
  2025</span></p>
  </td>
 </tr>
</table>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo
10&nbsp;mg/ml concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>crizanlizumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each 10&nbsp;ml
vial contains 100&nbsp;mg crizanlizumab.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Also contains:
sucrose, sodium citrate (E331), citric acid (E330), polysorbate 80 (E433),
water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100&nbsp;mg/10&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For intravenous
use after dilution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/20/1476/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>VIAL LABEL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Adakveo
10&nbsp;mg/ml sterile concentrate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>crizanlizumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.       METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100&nbsp;mg/10&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6.       OTHER</span></b></p>

</div>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Adakveo 10&nbsp;mg/ml concentrate for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>crizanlizumab</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><img border=0 width=21 height=18
id="Picture 1" src="Adakveo-4874%20EN%20PI_files/image035.png"
alt="BT_1000x858px"><span lang=EN-GB>This medicine is subject to additional
monitoring. This will allow quick identification of new safety information. You
can help by reporting any side effects you may get. See the end of
section&nbsp;4 for how to report side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you are given this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your doctor
or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or nurse.</span><span lang=EN-GB> This includes any possible side effects not
listed in this leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1.       What Adakveo
is and what it is used for</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.       What
you need to know before you are given Adakveo</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.       How Adakveo
is given</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4.       Possible
side effects</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5.       How to
store Adakveo</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6.       Contents
of the pack and other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>1.       What Adakveo is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Adakveo is</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo </span>contains
the active substance crizanlizumab, which belongs to a group of medicines
called monoclonal antibodies (mAbs).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>What Adakveo</b><b>
</b><b>is used for</b></p>

<p class=MsoNormal style='line-height:normal'>Adakveo is used to prevent recurrent
painful crises occurring in patients aged 16&nbsp;years and over with sickle
cell disease. Adakveo can be given in combination with
hydroxyurea/hydroxycarbamide, although it may also be used alone.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>Sickle cell disease is an
inherited blood disorder. It causes affected red blood cells to become sickle&#8209;shaped
and have difficulty passing through small blood vessels. Additionally in sickle
cell disease the blood vessels are damaged and sticky due to ongoing chronic
inflammation. This leads to blood cells sticking to the blood vessels, causing
acute episodes of pain and organ damage.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>How Adakveo
works</b></p>

<p class=MsoNormal style='line-height:normal'>Patients with sickle cell disease
have higher levels of a protein called P&#8209;selectin. Adakveo binds P&#8209;selectin.
This should stop blood cells sticking to the vessel walls and help prevent
painful crises.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>If you have any questions about
how Adakveo works or why this medicine has been prescribed for you, ask your <a
name="_Toc312231909"></a><span lang=EN-GB>doctor or nurse</span>.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>2.       What you need to know before you are given Adakveo</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>You must not be given Adakveo:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        if you are allergic to crizanlizumab or any
of the other ingredients of this medicine (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Infusion reactions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Medicines of this type (called monoclonal antibodies) are
administered into a vein (intravenously) as an infusion. They can cause
unwanted reactions (side effects) when they are infused into your body. Such
reactions may happen within 24&nbsp;hours of receiving an infusion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Tell your doctor or nurse immediately</span></b><span lang=EN-GB> if
you experience any of the following, which may be signs of an infusion reaction:</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever, chills, shivering, nausea, vomiting,
tiredness, dizziness, pain where the infusion needle is inserted, blisters,
itching, shortness of breath or wheezing. See also section&nbsp;4, “Possible
side effects”.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Your doctor or
nurse may monitor you for signs and symptoms of such infusion reactions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Blood tests during Adakveo treatment</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you need to
have any blood tests, tell the doctor or nurse that you are on treatment with Adakveo.
This is important because this treatment may interfere with a laboratory test
used to measure the number of platelets in your blood.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo </span>should
not be used in children or adolescents below 16&nbsp;years of age.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b>Other medicines and Adakveo</b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Tell your doctor
or nurse if you are taking, have recently taken or might take any other
medicines.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy and breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Adakveo has
not been tested in pregnant women therefore there is limited information about its
safety in pregnant women.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>If you are
pregnant, or are a woman who could become pregnant and is not using
contraception, it is not recommended to use Adakveo.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>It is not
known whether <span lang=EN-GB>Adakveo </span>or its individual ingredients
pass into breast milk.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>If you are
pregnant or breast&#8209;feeding, think you may be pregnant or are planning to
have a baby, ask your doctor for advice before receiving this medicine. Your doctor
will discuss with you the potential risk(s) of <span lang=EN-GB>Adakveo </span>during
pregnancy or breast&#8209;feeding.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Adakveo could have a minor effect on your ability to drive and use
machines. If you experience tiredness, drowsiness or dizziness, do not drive or
use machines until you feel better.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Adakveo contains sodium</span></b></p>

<p class=MsoNormal style='line-height:normal'>This medicine contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per vial, that is to say essentially “sodium&#8209;free”.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>3.       How Adakveo is given</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Adakveo will be given to you by a doctor or nurse.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
questions about how Adakveo is given, ask the doctor or nurse who is giving you
the infusion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Your doctor will
tell you when you will have your infusions and follow&#8209;up appointments.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>How much Adakveo you will be given</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose is 5&nbsp;mg per kilogram of body weight. You will be given the first infusion
at Week&nbsp;0 and the second infusion two weeks later (Week&nbsp;2). After
that you will be given an infusion every 4&nbsp;weeks.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>How the infusion is given</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo is
administered into a vein (intravenously) as an infusion lasting
30&nbsp;minutes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo can be given
alone or with hydroxyurea/hydroxycarbamide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>How long Adakveo treatment lasts</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You should
discuss with your doctor how long you will need to receive treatment. Your doctor
will regularly monitor your condition to check that the treatment is having the
desired effect.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget a Adakveo infusion</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is very
important that you receive all your infusions. If you miss an appointment for
an infusion, contact your doctor as soon as possible to reschedule.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you stop Adakveo treatment</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not stop Adakveo
treatment unless your doctor tells you that you can.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor or nurse.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.       Possible side
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Some side effects could be
serious</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Tell the doctor or nurse giving you the infusion immediately</span></b><span
lang=EN-GB> if you develop any of the following:</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever, chills, shivering, nausea, vomiting,
tiredness, dizziness, pain where the infusion needle is inserted, blisters,
itching, shortness of breath or wheezing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These symptoms
can be signs of infusion reaction, which is a common side effect (this means it
may affect up to 1 in every 10&nbsp;people).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in;line-height:
normal;page-break-after:avoid'><b>Other possible side effects</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Other
possible side effects include those listed below. If these side effects become
severe, tell your doctor or nurse.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Very
common (may affect more than 1 in 10&nbsp;people)</b></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>pain in the joints (arthralgia)</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>nausea</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>back pain</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>fever</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>pain in the lower or upper abdomen, feeling of tenderness in the abdomen
and abdominal discomfort</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Common
(may affect up to 1 in every 10&nbsp;people)</b></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>diarrhoea</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>itching (including vulvovaginal itching)</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>vomiting</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>muscle pain (myalgia)</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>pain in the muscles or bones of the chest (musculoskeletal chest pain)</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>sore throat (oropharyngeal pain)</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>redness or swelling and pain at the site of the infusion</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor or nurse. This includes any possible side effects not listed in this
leaflet.</span><span lang=EN-GB style='font-size:9.0pt'> </span><span
lang=EN-GB>You can also report side effects directly via <span
style='color:black;background:#D9D9D9'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:#D9D9D9'>Appendix V</span></a></span><span lang=EN-GB>.</span><span
lang=EN-GB> By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.       How to store Adakveo</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Do not
use this medicine after the expiry date which is stated on the outer carton and
the label after “EXP”. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light. Store in a refrigerator
(2°C&nbsp;–&nbsp;8°C). Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Infusion
solutions should be used immediately after dilution.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Adakveo contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is crizanlizumab. Each
10&nbsp;ml vial contains 100&nbsp;mg of crizanlizumab.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are sucrose, sodium
citrate </span>(E331)<span lang=EN-GB>, citric acid (E330), polysorbate 80
(E433) and water for injections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Adakveo looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo
concentrate for solution for infusion is a colourless to slightly brownish&#8209;yellow
liquid.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo is
available in packs containing 1&nbsp;vial.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Novartis
Pharma GmbH</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Roonstrasse
25</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>90429
Nuremberg</p>

<p class=MsoNormal style='line-height:normal'>Germany</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For any information about this medicine, please contact the local representative
of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=0
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-BE>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>Tél/Tel: +32 2
  246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>SIA Novartis
  Baltics Lietuvos filialas</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LT>Tel: +370 5 269
  16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=BG>&#1058;&#1077;&#1083;:</span>
  +359 2 489 98 28</p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-BE>Tél/Tel: +32 2
  246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&#268;eská
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +420 225
  775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=HU>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Novartis Hungária
  Kft. Pharma</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=HU>Tel.: +36 1 457
  65 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b>Danmark</b></p>
  <p class=MsoNormal style='line-height:normal'>Novartis Healthcare A/S</p>
  <p class=MsoNormal style='line-height:normal'>Tlf: +45 39 16 84 00</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=MT>Tel: +</span>356 <span
  lang=FR-CH>2122 2872</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Novartis Pharma
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: +49 911 273
  0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Novartis Pharma
  B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: +31 88 04 52
  555</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>SIA Novartis
  Baltics Eesti filiaal</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel: +372 </span><span
  lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Tlf: +47 23
  05 20 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Novartis (Hellas)
  A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;</span><span
  lang=ET>: +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-AT>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Novartis
  Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-AT>Tel: +43 1 86
  6570</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>España</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis
  Farmacéutica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: +34 93 306
  42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Novartis Poland
  Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel.: +48 22 375
  4888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Novartis Pharma
  S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tél: +33 1 55 47
  66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Novartis Farma &#8209;
  Produtos Farmacêuticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Tel: +351 21 000
  8600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Hrvatska
  d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel. +385 1
  6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=FR-CH>România</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR-CH>Novartis Pharma Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'>Tel: +40 21 31299 01</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 1
  260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Novartis Pharma
  Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SL>Tel: +386 1 300
  75 50</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IS>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IS>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sími</span><span
  lang=IS>: +354 535 7000</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SK>Slovenská
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Novartis Slovakia
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>Tel: +421 2 5542
  5439</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Novartis Farma
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +39 02 96 54
  1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Finland
  Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Puh/Tel: +358 </span><span
  lang=SV>(0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis
  Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;:
  +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Novartis Sverige
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Tel: +46 8 732 32
  00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FI>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>SIA Novartis
  Baltics</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Tel: +371 67 887
  070</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>United Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Novartis
  Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 1276
  698370</span></p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
has been given “conditional approval”. This means that there is more evidence
to come about this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency will review new information on this medicine at least every
year and this leaflet will be updated as necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: </span><span lang=EN-GB><span class=MsoHyperlink>http://www.ema.europa.eu</span></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>The following
information is intended for healthcare professionals only:</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo vials
are for single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Preparing the infusion</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The diluted
solution for infusion  should be prepared by a healthcare professional using
aseptic techniques.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The total dose
and required volume of Adakveo depend on the patient’s body weight; 5&nbsp;mg
of crizanlizumab is administered per kg body weight.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The volume to be used for the preparation of the infusion is
calculated according to the following equation:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=567
 style='margin-left:12.5pt;border-collapse:collapse'>
 <tr>
  <td width=113 rowspan=2 style='width:85.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>Volume (ml) =</span></p>
  </td>
  <td width=359 style='width:269.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
  text-indent:-28.35pt;line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Patient’s body weight (kg) x prescribed dose</span></p>
  </td>
  <td width=94 style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
  text-indent:-28.35pt;line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>[5&nbsp;mg/kg]</span></p>
  </td>
 </tr>
 <tr>
  <td width=359 style='width:269.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>Concentration
  of Adakveo</span></p>
  </td>
  <td width=94 style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Text align=center style='margin-top:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>[10&nbsp;mg/ml]</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1.       Obtain the number of
vials required to deliver the prescribed dose and bring them to room
temperature (for a maximum of 4&nbsp;hours). One vial is needed for every
10&nbsp;ml of Adakveo (see below table).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=568
 style='margin-left:28.35pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Body weight (kg)</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Dose (mg)</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Volume (ml)</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><b><span lang=EN-GB>Vials (n)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>40</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>200</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>20</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>2</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>60</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>300</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>30</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>3</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>80</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>400</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>40</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>100</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>500</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>50</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>5</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=140 valign=top style='width:104.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>120</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>600</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>60</span></p>
  </td>
  <td width=153 valign=top style='width:114.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB>6</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>2.       Visually inspect the vials.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The solution in the vials should be clear to
opalescent. Do not use if particles are present in the solution.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The solution should be colourless or may have a
slight brownish&#8209;yellow tint.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>3.       Withdraw a volume
equal to the required volume of Adakveo from a 100&nbsp;ml infusion bag
containing either sodium chloride </span><span lang=EN-GB>9&nbsp;mg/ml (</span><span
lang=EN-GB>0.9%) solution for injection or dextrose 5% and discard.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>No incompatibilities between the diluted Adakveo
solution and infusion bags composed of polyvinylchloride (PVC), polyethylene
(PE) and polypropylene (PP) have been observed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4.       Withdraw the necessary
volume of Adakveo from the vials and inject slowly into the previously prepared
infusion bag.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The </span><span lang=EN-GB>solution</span><span
lang=EN-GB> must not be mixed or co&#8209;administered with other medicinal
products through the same intravenous line.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep the volume of Adakveo added to the infusion
bag in the range of 10&nbsp;ml&nbsp;to&nbsp;96&nbsp;ml to obtain a final
concentration in the infusion bag within 1&nbsp;mg/ml to 9.6&nbsp;mg/ml.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5.       Mix the
diluted solution by gently inverting the infusion bag. DO NOT SHAKE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Storage of the diluted solution</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Chemical and
physical in&#8209;use stability, from the start of preparation of the diluted
solution for infusion until end of infusion, has been demonstrated for up to
8&nbsp;hours at room temperature (up to 25°C) and at 2°C to 8°C for up to 24&nbsp;hours
overall.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>From a
microbiological point of view, the diluted solution for infusion should be used
immediately. If not used immediately, in&#8209;use storage times and conditions
prior to use are the responsibility of the user and would normally not be
longer than 24&nbsp;hours at 2°C to 8°C, including 4.5&nbsp;hours at room
temperature (up to 25°C) from the start of preparation to completion of the
infusion, unless dilution has taken place in controlled and validated aseptic
conditions.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adakveo diluted </span><span
lang=EN-GB>solution must be administered through a sterile, non&#8209;pyrogenic
0.2&nbsp;micron in&#8209;line filter</span><span lang=EN-GB> by intravenous
infusion over a period of 30&nbsp;minutes.</span><span lang=EN-GB> No
incompatibilities have been observed between Adakveo and infusion sets composed
of PVC, PE&#8209;lined PVC, polyurethane, and in&#8209;line filter membranes
composed of polyethersulfone (PES), polyamide (PA) or polysulphone (PSU).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
administration of Adakveo, flush the line with at least 25&nbsp;ml sodium
chloride 9&nbsp;mg/ml (0.9%) solution for injection or dextrose 5%.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Disposal</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
product or waste material should be disposed of in accordance with local
requirements.</span></p>

</div>

</body>

</html>
